A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

505

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Lebrikizumab
DRUG: Pirfenidone
DRUG: Placebo

Sponsor

Hoffmann-La Roche